Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis. Several patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback